Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

cinacalcet

Known as: (R)-alpha-Methyl-N-[3-[3-(trifluoromethyl)phenyl]propyl]-1-naphthalenemethane amine, CNC, N-((1R)-1-(Naphthalen-1-yl)ethyl)-3-(3-(trifluoromethyl)phenyl)propan-1-amine 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2012
Highly Cited
2012
BACKGROUND Disorders of mineral metabolism, including secondary hyperparathyroidism, are thought to contribute to extraskeletal… Expand
  • figure 1
  • table 1
  • table 2
Is this relevant?
Highly Cited
2011
Highly Cited
2011
BACKGROUND This prospective, randomized, controlled trial compared the progression of vascular and cardiac valve calcification in… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Is this relevant?
Highly Cited
2010
Highly Cited
2010
BACKGROUND AND OBJECTIVES Cinacalcet is effective in reducing serum parathyroid hormone (PTH) in patients with secondary… Expand
  • table 1
  • figure 2
  • figure 1
  • figure 3
  • table 3
Is this relevant?
Highly Cited
2009
Highly Cited
2009
CONTEXT Primary hyperparathyroidism (PHPT) is characterized by chronically elevated serum calcium and inappropriately normal or… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2008
Highly Cited
2008
BACKGROUND AND OBJECTIVES Cinacalcet, a novel calcimimetic, targets the calcium-sensing receptor to lower parathyroid hormone… Expand
  • figure 1
  • table 1
  • table 2
  • figure 3
  • figure 2
Is this relevant?
Highly Cited
2008
Highly Cited
2008
AIMS Cinacalcet lowers plasma parathyroid hormone (PTH) levels in patients with secondary hyperparathyroidism (sHPT), but the… Expand
Is this relevant?
Highly Cited
2005
Highly Cited
2005
BACKGROUND Secondary hyperparathyroidism (HPT) and abnormal mineral metabolism are thought to play an important role in bone and… Expand
Is this relevant?
Highly Cited
2005
Highly Cited
2005
BACKGROUND The National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (NKF-K/DOQItrade mark) has established… Expand
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Management of secondary hyperparathyroidism is challenging with traditional therapy. The calcimimetic cinacalcet HCl acts on the… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Calcimimetic compounds, which activate the parathyroid cell Ca2+ receptor (CaR) and inhibit parathyroid hormone (PTH) secretion… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 5
  • figure 4
Is this relevant?